Parasitology is a challenge. At one level, the structural and genetic complexities of parasites provide ample technical challenges in regard to an understanding of parasite variability and adaptability, epidemiological diversity, drug resistance, etc. The intricacies of host parasite relationships including the immunology of parasitism will continually surprise yet frustrate the vaccine developer and keep the bravest immunoparasitologist busy and creative for decades. As if the technical considerations were not challenging enough, we see difficulties arising in sustaining a research endeavour and preserving a critical mass of researchers through the generation of high-level, long-term funding support. Contributing to this situation is the fact that most parasitic diseases of major impact in humans are largely centred around the rural poor in tropical, less industrially-developed countries and therefore of little or of fickle interest to the strictly commercially oriented. Moreover, the focus in the rural industries has moved away from aspects of on-farm production with lower priority given to studies on even the 'economically-important' parasites of livestock. It is contended that this may change again with pressures and clear marketing advantages to preserving a 'clean and green' image for Australia's primary industries. Overall, the extraordinary technical and conceptual advances in recent times have been tempered by uncertainties in research funding and severe cuts from some traditional sources for both fundamental and strategic/applied research in Parasitology. Several have highlighted the fact that deliverables in terms of new methods of disease control have been sparse and some claims made in the past have certainly been exaggerated. Yet the prospects and achievements at the front end of the long R&D pathway have never been brighter. In this article we examine the merits of a 'portfolio approach' to generating research funds in Parasitology and Science and Technology in Australia more generally, with an emphasis on strategies that, through welding good science with clear, medium-term product objectives, increase research funding opportunities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0020-7519(99)00053-3 | DOI Listing |
J Clin Psychol
January 2025
Department of Clinical Psychology and Psychobiology, The Institute of Neurosciences, Universitat de Barcelona, Barcelona, Spain.
Based on the repertory grid technique, we developed Explore Your Meanings (EYME), a digital platform that helps patients explore identity values and internal conflicts using virtual reality (VR). EYME was part of a research project treating depression in young adults, including 10 weekly, 1-h sessions aimed at changing personal constructs-cognitive schemas that shape how individuals interpret reality. We present the case of Mary, a 21-year-old woman diagnosed with persistent major depressive disorder and social phobia.
View Article and Find Full Text PDFPaediatr Drugs
January 2025
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
Background: This study aimed to provide a comprehensive review of adverse events (AEs) associated with factor Xa (FXa) inhibitors in pediatric patients.
Methods: We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and the European Union Clinical Trials Register for English-language records from the establishment of the database up to October 17, 2023.
Infect Dis Ther
January 2025
ViiV Healthcare, Madrid, Spain.
Introduction: Dolutegravir (DTG) + lamivudine (3TC) demonstrated high rates of virologic suppression (VS) and low rates of virologic failure (VF), discontinuation, and drug resistance in randomized trials. Real-world evidence can support treatment effectiveness, safety, and tolerability in clinical practice and aid in treatment decisions.
Methods: A systematic literature review (SLR) was conducted to identify studies using DTG + 3TC (January 2013-March 2024).
Indian J Gastroenterol
January 2025
Department of Gastroenterology, Christian Medical College, Vellore, 632 517, India.
Background: Groove pancreatitis (GP) is a form of pancreatitis that affects the pancreaticoduodenal groove area, which lies between the head of the pancreas, the second part of the duodenum and the distal bile duct, presenting as abdominal pain and gastric outlet obstruction. In this study, we present the clinical and radiological characteristics of individuals diagnosed with groove pancreatitis at our center and discuss the use of a conservative treatment approach in managing GP.
Methods: The data of patients with groove pancreatitis treated at our center between January 2012 and December 2021 was analyzed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!